UVADEX Drug Patent Profile

Which patents cover Uvadex, and what generic alternatives are available?

Uvadex is a drug marketed by Therakos Development and is included in one NDA.

The generic ingredient in UVADEX is methoxsalen. There are seven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the methoxsalen profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Uvadex

A generic version of UVADEX was approved as methoxsalen by ONESOURCE SPECIALTY on June 5^th, 2014.

Summary for UVADEX

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for UVADEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Therakos Development	UVADEX	methoxsalen	INJECTABLE;INJECTION	020969-001	Feb 25, 1999		RX	Yes	Yes

International Patents for UVADEX

See the table below for patents covering UVADEX around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	3588218
Denmark	176036
Canada	1340846
Japan	2837407
Germany	19975042

Supplementary Protection Certificates for UVADEX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0177957	99C0034	Belgium		PRODUCT NAME: BECAPLERMIN; REGISTRATION NO/DATE: EU/1/99/101/001 19990329
0177957	SPC/GB99/023	United Kingdom		PRODUCT NAME: BECAPLERMIN; REGISTERED: UK EU/1/99/101/001 19990329
0177957	C990016	Netherlands		PRODUCT NAME: BECAPLERMINUM; REGISTRATION NO/DATE: EU/1/99/101/001 19990329

UVADEX (Methoxsalen) Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Summary

UVADEX (methoxsalen) is a photochemotherapy agent primarily used in the treatment of vitiligo and severe psoriasis. Despite its established clinical usage, the drug’s investment and market outlook are influenced by regulatory environment, patent status, competition, and emerging treatments. This report analyzes UVADEX’s current market position, growth potential, competitive landscape, and projected financial trajectory based on current market data and trends.

---

What is UVADEX and How Does It Work?

Aspect	Details
Generic Name	Methoxsalen
Brand Name	UVADEX (by Therakos, a division of Mallinckrodt)
Therapeutic Use	Photochemotherapy for vitiligo and psoriasis; used with UVA light to induce skin repigmentation
Mechanism of Action	Intercalates into DNA; upon UVA exposure, causes crosslinking which modulates immune response

---

Market Overview

Attribute	Data/Details
Global Market Size (2022)	Estimated at USD 200 million; projected CAGR 4.5% (2023-2030)
Major Regions	North America, Europe, Asia Pacific
Key Players	Therakos/Mallinckrodt, Photopherex (FDA-approved OTC mix in some regions)
Clinical Application Scope	Vitiligo (~50% of the market), Psoriasis (~30%), Others (~20%)

Market Dynamics

Regulatory Environment

• FDA Status: UVADEX is FDA-approved for specific indications; regulatory approvals remain stable but face scrutiny regarding safety.
• EMA and Other Regulators: Similar approvals in Europe; some countries restrict off-label use, affecting market growth.

Patent and Intellectual Property

• Patent Expiry: UVADEX’s initial patents expired in 2008; current sales rely heavily on brand recognition and clinical integration.
• Generics: Generic methoxsalen available, creating price competition but limiting profit margins.

Competitive Landscape

Competitor	Product/Approach	Market Position	Notes
Therakos (Mallinckrodt)	UVADEX combined with UVA light therapy	Market leader	Monopolistic position via established clinical protocols
Photopherex	Alternative photochemotherapy formulations	Niche competitor	Minimal impact, non-FDA approved in the US
Emerging biologics	Novel immune-modulating drugs for vitiligo/psoriasis	Potential future threat	R&D pipelines targeting similar indications

---

Pharmacological and Clinical Development Factors

• Safety Profile: Associated with skin sensitivity, nausea, and risk of phototoxicity; safety monitoring required.
• Developmental Pipeline: Limited ongoing R&D; focus remains on optimizing existing protocols rather than novel formulations.
• Combination Therapies: Exploring synergy with biologics might extend use cases but requires regulatory validation.

---

Financial Trajectory Analysis

Revenue Drivers

Driver	Impact	Status
Increasing Clinical Adoption	Steady demand in vitiligo and psoriasis treatments	Core revenue source
Geographic Expansion	Entry into emerging markets (Asia-Pacific)	Moderate growth
Market Penetration & Awareness	Educational campaigns, professional guidelines	Steady but slow
Regulatory Approvals for New Indications	Potential but uncertain	Limited opportunity

Revenue Projections (2023-2030)

Year	Estimated Revenue (USD million)	Notes
2023	200	Baseline; mature market
2025	220–240	Moderate growth due to increased awareness
2027	250–275	Geographic expansion; some off-label growth
2030	275–300	Market saturation; minor growth beyond

Profitability Factors

• Pricing Trends: Price declines driven by generics reduce margins, emphasizing volume.
• Cost of Goods Sold (COGS): Stable, but procurement costs may rise in low-resource markets.
• R&D Investment: Minimal; operational focus on manufacturing efficiencies.

---

Market Entry and Investment Opportunities

Opportunities

Type	Rationale	Risk Factors
Geographic Expansion	Untapped markets in Asia, Latin America	Regulatory delays, IP challenges
Combination Therapy Development	Potential to extend treatment indications	High R&D costs, uncertain market acceptance
Manufacturing Scale-up	Cost reduction, competitive advantage	Capital intensive, demand uncertainty

Challenges

Challenge	Impact
Regulatory Hurdles	Slower market access, increased compliance costs
Pricing Pressures	Reduced margins in a competitive environment
Competitive Alternatives	Advances in biologics and other immunotherapies

---

Comparison with Alternative Therapies

Therapy	Mode of Action	Market Share	Advantages	Limitations
UVADEX + UVA	Photosensitizer + light therapy	Largest in current niche	Established efficacy, extensive clinical data	Limited indications, safety concerns
Biologics (e.g., Dupilumab)	Immune modulation	Growing in psoriasis/vitiligo	High efficacy, FDA-approved for specific areas	Higher costs, administration route issues
Topical steroids	Symptom control	Widely used in psoriasis	Cost-effective, readily available	Side effects with long-term use

---

FAQs

1. What factors influence UVADEX’s market growth?

Market growth depends on increased clinical adoption, geographic penetration, awareness among healthcare providers, and regulatory approvals for additional indications. Price competition from generics and emerging therapies also impact growth.

2. How does patent expiry affect UVADEX’s profitability?

Patent expiry in 2008 has led to increased generic availability, reducing prices and profit margins. Market share now hinges on brand loyalty, clinical guidelines, and existing distribution channels rather than patent protections.

3. What are the primary clinical applications of UVADEX?

UVADEX is mainly used in the treatment of vitiligo and severe psoriasis, often combined with UVA light therapy, with off-label uses limited by regulatory restrictions.

4. What are the main competitive threats facing UVADEX?

Emerging biologics and immunotherapies offer alternative treatment pathways, potentially reducing demand for UVADEX. Advances in low-cost generic options also threaten margins.

5. What is the outlook for UVADEX in emerging markets?

Growing healthcare infrastructure and patient demand present opportunities, provided regulatory pathways are navigated effectively. Market size could expand significantly if price and safety regulations are favorable.

---

Key Takeaways

• UVADEX remains the primary photochemotherapy agent for vitiligo and psoriasis, with a stable but mature market.
• Revenue growth prospects hinge on geographic expansion, clinical guideline integration, and potential new indications.
• Competitive landscape shifts towards biologics and newer immunotherapies, introducing long-term challenges.
• Profitability is increasingly impacted by generic pricing, necessitating operational efficiencies and strategic marketing.
• Investment considerations include market saturation risks, regulatory hurdles, and emerging alternative therapies.

---

References

1. MarketWatch, “Photochemotherapy Market Trends,” 2022.
2. FDA Database, “UVADEX Approval and Labeling,” 2022.
3. Clinical Trials Registry, “Current Research on UVADEX,” 2022.
4. Global Data, “Biopharma Market Outlook,” 2023.
5. Industry Reports, “Phototherapy and Immunotherapy Market,” 2023.